Articles Vol. 67 No. Số CĐ12- Bệnh viện Ung bướu Nghệ An (2026) 25/08/2026

CLINICAL AND LABORATORY PROFILES OF PATIENTS WITH PRIMARY MYELOFIBROSIS AT THE NATIONAL INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION BETWEEN 2019 AND 2024

Nguyen Ba Cuong1,2, Le Quang Chiem1,2, Nguyen Vu Bao Anh1,2,3,4, Phi Thi Nguyet Anh1,2, Le Thi Thu1,2, Le Quoc Anh1,2, Nguyen Ngoc Ban2,5, Vu Dinh Hung2,5, Vu Duc Binh1,2,3,4
1 National Institute of Hematology and Blood Transfusion
2 Viện Huyết học Truyền máu Trung Ương
3 Hanoi Medical University
4 Trường Đại học Y Hà Nội
5 National Institute of Hematology and Blood TransfusionNational Institute of Hematology and Blood Transfusion
DOI: 10.52163/yhc.v67iCD12.6287
261 Views
0 Downloads
Keywords
Primary myelofibrosis, National Institute of Hematology and Blood Transfusion, Vietnam.
Abstract

Objective: To describle the clinical and laboratory profiles of patients with primary myelofibrosis (PMF) at the National Institute of Hematology and Blood Transfusion (NIHBT) between 2019 and 2024.

Methods: A cross-sectional descriptive study was conducted on 181 PMF patients managed at the NIHBT from January 2019 to December 2024.

Results: The cohort’s mean age was 62.7 ± 11.8 years, with a predominance of patients aged over 60. Constitutional symptoms were prevalent, including fatigue (89%), early satiety (70.2%), abdominal discomfort (70.2%), left upper quadrant pain (70.2%), and weight loss (63%). Physical examination revealed a high incidence of splenomegaly (95.6%) and anemia (89%).

Laboratory findings indicated that 90.6% of patients presented with anemia (Hb≤120 g/L). Platelet counts were variable: 26.5% exhibited thrombocytosis (≥450 G/L), while 14.9% had thrombocytopenia (< 50 G/L). Leukocytosis (≥11 G/L) was observed in 51.4% of the cases. Bone marrow evaluation showed erythroid hypoplasia in 85.6% of patients; granulocytic lineage was increased in 42.5% and decreased in 17.1%, while 73.5% demonstrated megakaryocytic hyperplasia. Bone marrow fibrosis was classified as Grade II in 64.6% and Grade III in 35.4% of patients. The prevalence of the JAK2 mutation was 67.1%, whereas CALR and MPL mutations were identified in 3.9% and 1.1% of the cohort, respectively.

Conclusion: Primary myelofibrosis patients present with heterogeneous clinical manifestations, characterized by high frequencies of splenomegaly and anemia. Laboratory analyses frequently reveal trilineage hematopoietic dysregulation in the bone marrow.

References
[1]
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200-28. Google Scholar
[2]
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405. Google Scholar
[3]
de Freitas RM, da Costa Maranduba CM. Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview. Revista brasileira de hematologia e hemoterapia. 2015;37(5):348-53. Google Scholar
[4]
Tefferi A. Myelofibrosis with myeloid metaplasia. The New England journal of medicine. 2000;342(17):1255-65. Google Scholar
[5]
Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(5):573-82. Google Scholar
[6]
Phạm Thị Yến Thư. Một số đặc điểm lâm sàng và xét nghiệm máu ngoại vi ở bệnh nhân xơ tủy nguyên phát tại Viện Huyết học - Truyền máu Trung Ương. Tạp chí Y học Việt Nam. 2023;530(1):88-91. Google Scholar
[7]
Nguyễn Ngọc Dũng, Hải Quân. Một số đặc điểm của tủy xương ở bệnh nhân xơ tủy nguyên phát tại Viện Huyết học - Truyền máu Trung Ương. Tạp chí Y học Việt Nam. 2023;530(1):230-3. Google Scholar
[8]
Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood cancer journal. 2018;8(2):15. Google Scholar
[9]
Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach. Seminars in hematology. 2005;42(4):184-95. Google Scholar
[10]
Verstovsek S, Yu J, Scherber RM, Pandya S, Dieyi C, Chen C-C, et al. Changes in the Incidence and Overall Survival of Patients with Myeloproliferative Neoplasms between 2002 and 2016 in the United States. Blood. 2020;136:12-3. Google Scholar
[11]
Nguyễn Vũ Bảo Anh. Nghiên cứu đặc điểm lâm sàng, xét nghiệm và điều trị một số bệnh tăng sinh tủy ác tính giai đoạn 2015-2018 tại Viện Huyết học - Truyền máu Trung Ương. Hà Nội: Đại học Y Hà Nội; 2023. Google Scholar
[12]
Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-901. Google Scholar
[13]
Gong X, Lu X, Xiao X, Wang W, Yang J, Fu Y, et al. Clinicopathologic characteristics of prefibrotic-early primary myelofibrosis in Chinese patients. Hum Pathol. 2014;45(3):498-503. Google Scholar
[14]
Vũ Đức Bình, Lê Thị Thu. Bước đầu đánh giá hiệu quả điều trị bằng ruxolitinib ở bệnh nhân xơ tủy nguyên phát tại Viện Huyết học - Truyền máu Trung Ương giai đoạn 2019-2024. Tạp chí Y học Việt Nam. 2025;550(1):363-8. Google Scholar
[15]
Yap YY, Law KB, Sathar J, Lau NS, Goh AS, Chew TK, et al. The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia. Experimental hematology & oncology. 2018;7:31. Google Scholar
[16]
Song J, Hussaini M, Zhang H, Shao H, Qin D, Zhang X, et al. Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. Am J Clin Pathol. 2017;147(5):444-52. Google Scholar